Mr Mark Glyn Hardy
Mr Mark Glyn Hardy was appointed in a total of 33 companies and resigned from 12 of these appointments.
Roles
Director • Secretary
Country Of Residence
United Kingdom
Nationality
British
Date of Birth
June 1953
Occupations
Solicitor • Unreported • Lawyer
Active
3
Resigned
12
Dissolved
14
Other
4
Total
33
Companies
| Company | Timeline | Status | |
| Celltech Group Limited Director • Solicitor | 11 Jun 2009←14 Years→1 Oct 2023 | Active | |
| Schwarz Pharma Limited Director • Solicitor | 1 Dec 2007←13 Years→12 Jan 2021 | Dissolved | |
| Schwarz Pharma Limited Secretary • Solicitor | 1 Dec 2007←13 Years→12 Jan 2021 | Dissolved | |
UCB Bridgwater Pension Trust Limited Director • Director | 25 Nov 2005←13 Years→26 Mar 2019 | Dissolved | |
UCB British Pension Trust Limited Director • Solicitor | 18 Oct 2005←11 Years→21 Feb 2017 | Dissolved | |
Fipar UK Limited Secretary • Unreported | 18 Feb 2005←13 Years→21 Jun 2018 | Dissolved | |
UCB Fipar Limited Director • Solicitor | 18 Feb 2005←13 Years→9 Jul 2018 | Dissolved | |
UCB Fipar Limited Secretary • Unreported | 18 Feb 2005←13 Years→9 Jul 2018 | Dissolved | |
Fipar UK Limited Director • Solicitor | 18 Feb 2005←13 Years→21 Jun 2018 | Dissolved | |
| UCB (Investments) Limited Director • Solicitor | 31 Dec 2004←18 Years→1 Oct 2023 | Active | |
Mutual People
- Mr Stephen Charles JonesUCB Fipar Limited, Medeva UK Pension Limited, Darwin Discovery Limited, and 11 more are mutual companies.
- John Andrew Duncan SlaterUCB Ireland, Celltech Japan Limited, International Medication Systems (U.K.) Limited, and 9 more are mutual companies.
- Harbinder Singh BainsMedeva UK Pension Limited, UCB Pharma Limited, Celltech Pension Trustees Limited, and 5 more are mutual companies.
- Claire BradingCelltech Group Limited, UCB (Investments) Limited, UCB Pharma Limited, and 2 more are mutual companies.
Financials, Credit Activity, Owners, and more
Completely understand the businesses you work with
Make key decisions on clients and suppliers faster, discover leads and connect with decision makers, and easily monitor opportunities that get better through time
